Strategy focused on profitability by end of 2024,
using current cash on hand

New leadership to host conference call and webcast
today at 4:30 PM ET

NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today reported its financial and operating
results for the twelve months ended
December 31, 2022.


  • Company continues
    to invest in Detection business, driving commercial growth through global
    adoption of Breast AI Suite while exploring strategic options for Therapy
  • Several strategic
    partnership agreements signed in Q4, including Google Health and Solis Mammography,
    positioning the Company for growth
  • Promising clinical
    research reaffirms clinical value and utility of Breast AI Suite
  • Company reduces
    annualized expenses by $4.3 to $4.6 million and decreases annualized cash burn by
    $4.9 to $5.2 million

View Webcast

Full Results